ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: Strohl Leads Oncology Nursing Society; ONS Seeks Nominees For Consumer Panel

June 4, 1999

In Brief: Jay Moskowitz Reassigned; Healy To Run For Ohio Republican Nomination To Senate

September 17, 1993

High-Dose Chemo Doesn’t Improve Survival In Small Cell Lung Cancer

April 25, 2008

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

January 31, 2003

John Ultmann, Chicago’s Outspoken Director, Heads In Retirement

August 30, 1991

ASCO Urges Doubling Cooperative Group Program Budget

April 16, 2010